|
T73335 |
P2X7-IN-2
|
|
|
|
P2X7-IN-2, a P2X7 receptor inhibitor, effectively suppresses IL-Iβ release, demonstrating an inhibitory concentration (IC50) value of 0.01 nM. This compound is utilized in the study of autoimmunity, inflammation, and car... |
|
T81579 |
P2X7 receptor antagonist-4
|
|
|
|
Compound 14a (P2X7 receptor antagonist-4) is a P2X7R antagonist with IC50 values of 64.7 nM in humans and 10.1 nM in mice. It inhibits the activation of the NLRP3 inflammasome, which subsequently reduces the expression o... |
|
T62488 |
P2X7 receptor antagonist-1
|
|
|
|
P2X7 receptor antagonist-1 is a purinergic P2X7 receptor antagonist with anti-neuroinflammatory effects. |
|
T61566 |
P2X7 receptor antagonist-2
|
|
|
|
P2X7 receptor antagonist-2 is a highly potent antagonist of the P2X7 receptor, exhibiting a pIC50 value range of 6.5-7.5. Its efficacy in combating neuroinflammation has been demonstrated [1]. |
|
T72198 |
P2X7 receptor antagonist-3
|
|
|
|
P2X7 receptor antagonist-3 is a powerful inhibitor of the P2X7 receptor, exhibiting IC50 values of 4.2 nM in humans and 6.8 nM in rats, indicating its high potency in both species. |
|
T75254 |
P2X7-IN-2 TFA
|
|
|
|
P2X7-IN-2 TFA (compound 58) is a P2X7 receptor inhibitor that demonstrates the capability to inhibit IL-Iβ release effectively with an IC50 value of 0.01 nM. It is utilized in research focused on autoimmunity, inflammati... |
|
T4298 |
JNJ-47965567
|
JNJ-479655 |
P2X Receptor
|
|
JNJ-47965567 (JNJ-479655) is a selective antagonist of the purinergic receptor P2X subtype 7 (P2X7), a ligand-gated ion channel(with pKis of 7.9 and 8.7 for human and rat P2X7, respectively). |
|
T9786 |
Lu AF27139
|
|
P2X Receptor
|
|
Lu AF27139 is an effective and selective antagonist of P2X7 receptor (IC50s of 12 and 2.4 nM for human and rat, Kis of 22, 54, and 13 nM for mouse, human, and rat, respectively). Lu AF27139 can be used in CNS diseases st... |
|
T14076 |
A 839977
|
A839977,A-839977 |
P2X Receptor
,
Calcium Channel
|
|
A 839977 is a selective P2X7 receptor antagonist with anti-inflammatory and analgesic activity that inhibits BzATP-induced calcium efflux from the P2X7 receptor for the study of renal fibrosis. |
|
T2673 |
A 438079 hydrochloride
|
A 438079 (hydrochloride),A-438079 hydrochloride,A-438079 HCl |
P2X Receptor
|
|
A 438079 hydrochloride (A-438079 HCl) is a potent and selective P2X7 receptor antagonist with pIC50 of 6.9. |
|
T10207 |
A 438079
|
|
P2X Receptor
|
|
A 438079 is a potent, and selective antagonist of P2X7 receptor (pIC50: 6.9). |
|
T14385 |
AZD9056 hydrochloride
|
|
P2X Receptor
|
|
AZD9056 hydrochloride is a P2X7 inhibitor，Which plays a significant role in pain-causing diseases and inflammation. |
|
T15622 |
JNJ-54175446
|
JNJ-5446 |
P2X Receptor
|
|
JNJ-54175446 (JNJ-5446) is a CNS-permeable and selective P2X7 receptor antagonist that attenuates the release of IL-1β/IL-18 from microglia, and may be used in the study of depression. |
|
T27683 |
JNJ-42253432
|
|
P2X Receptor
|
|
JNJ-42253432 is an oral active P2X7 antagonist capable of penetrating the central nervous system with a pKi value of 9.1 for rat and 7.9 for human P2X7 channels. |
|
T3690 |
A-740003
|
A 740003 |
P2X Receptor
|
|
A-740003 (A 740003) is an effective and specific P2X7 receptor antagonist (IC50: 18/40 nM, for rat/human). It can reduce nociception in animal models of persistent neuropathic and inflammatory pain, and also reduce neuro... |
|
T7805 |
GW791343 dihydrochloride
|
GW791343 (HCl) |
P2X Receptor
|
|
GW791343 dihydrochloride (GW791343 (HCl)) is a P2X7 allosteric modulator. |
|
T61025 |
GSK-1482160
|
|
P2X Receptor
|
|
GSK-1482160 is a CNS-penetrant negative allosteric modulator of P2X7 receptor with oral activity. The P2X7 receptor is involved in the production of pro-inflammatory cytokines by central and peripheral immune cells, so G... |
|
TP2226 |
BzATP triethylammonium salt
|
|
P2X Receptor
|
|
BzATP triethylammonium salt is a P2X7 receptor agonist. |
|
T21659 |
AZ 11645373
|
3-[1-[[(3'-NITRO[1,1'-BIPHENYL]-4-YL)OXY]METHYL]-3-(4-PYRIDINYL)PROPYL]-2,4-THIAZOLIDINEDIONE |
P2X Receptor
|
|
AZ 11645373 (3-[1-[[(3'-NITRO[1,1'-BIPHENYL]-4-YL)OXY]METHYL]-3-(4-PYRIDINYL)PROPYL]-2,4-THIAZOLIDINEDIONE) is a highly selective and potent human P2X7 receptor antagonist that has no effect on mouse/rat P2X7 receptor. |
|
T3639 |
A-804598
|
A 804598 |
P2X Receptor
|
|
A-804598 is a competitive and selective P2X7 receptor antagonist (IC50: 10 nM, rat; 9 nM, mouse; 11 nM, human). |
|
T14920 |
CE-224535
|
PF-04905428 |
P2X Receptor
|
|
CE-224535 (PF-04905428) is a selective antagonist of P2X7 receptor. CE-224535 can be used in disease-modifying antirheumatic studies. |
|
T19839 |
Oxatomide
|
Oxatomida |
P2X Receptor
,
Calcium Channel
,
5-HT Receptor
,
Histamine Receptor
|
|
Oxatomide (Oxatomida) is a potent and orally active dual H1 histamine receptor and P2X7 receptor antagonist with antihistamine and antiallergic activity.Oxatomide can be used to block ATP-induced currents in the human P2... |
|
T37806 |
JNJ-55308942
|
|
P2X Receptor
|
|
JNJ-55308942 is a selective and brain-penetrant antagonist of P2X7 functional with IC50s of 10 and 15 nM and Kis of 7.1 and 2.9 nM for hP2X7 and rP2X7, respectively. |
|
T20731 |
Brilliant blue G-250
|
BBG,Acid blue 90, Coomassie Brilliant Blue G,Brilliant Blue G |
P2X Receptor
|
|
Brilliant blue G-250 (Acid blue 90, Coomassie Brilliant Blue G) is an antagonist of the P2X7 purinergic receptor. |
|
T2694 |
KN-62
|
|
CaMK
,
P2X Receptor
,
Autophagy
|
|
KN-62 is a potent and specific Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor with Ki of 0.9 μM. |
|
T14366 |
AZ10606120 dihydrochloride
|
|
P2X Receptor
|
|
AZ10606120 dihydrochloride is a selectable, potent, high-affinity receptor antagonist with K D values of 1.4 and 19 nM at human and rat P2X 7 receptors, respectively. AZ10606120 dihydrochloride inhibits tumor growth and ... |
|
T6526 |
GW791343 trihydrochloride
|
GW791343 3HCl |
P2X Receptor
|
|
GW791343 trihydrochloride (GW791343 3HCl) is aHCl salt form of GW791343, which is a non-competitive allosteric modulator of human P2X7 receptor inhibitor with pIC50 of 7. |
|
T30267 |
AZD-9056 free base
|
AZD9056,AZD 9056,AZD-9056 |
|
|
AZD9056 is a potent, selective, orally bioavailable P2X7 receptor antagonist. |
|
T27688 |
JNJ-54166060
|
|
|
|
JNJ-54166060 is a potent and selective antagonist of P2X7 receptor, with IC 50 s of 4/115/72 nM for human/rat/mouse P2X7 receptor, respectively [1]. |
|
T26700 |
AZ11657312 Free Base
|
AZ-11657312,AZ11657312,AZ 11657312 |
|
|
AZ11657312 is a P2X7 receptor antagonist. |
|
T13541 |
α,β-Methylene ATP trisodium
|
|
Others
|
|
α,β-Methylene ATP trisodium is a ligand of P2X3 and P2X7 receptor. |
|
T74409 |
EVT-401
|
|
|
|
EVT-401 (P2X7 receptor antagonist-1), a purinergic P2X7 receptor antagonist, demonstrates efficacy in combating neuroinflammation [1]. |
|
T38444 |
α,β-Methylene-ATP dilithium
|
|
|
|
α,β-Methylene ATP dilithium, a phosphonic analog of ATP, serves as a ligand for P2X3 and P2X7 receptors. It is a potent agonist specifically targeting P2X1 and P2X3 receptors while exerting negligible activity on P2X2, P... |
|
T73880 |
(S)-JNJ-54166060
|
|
|
|
(S)-JNJ-54166060, an enantiomer of JNJ-54166060, functions as a potent antagonist of P2X7 [1]. |
|
T27450 |
GSK1482160
|
GSK 1482160,GSK-1482160 |
|
|
GSK1482160 is a potent and selective P2X7 receptor allosteric modulator. |
|
T68668 |
AZ-1
|
|
|
|
AZ-1 is an inducer of ABCA1 and apoE. It enhances ABCA1 activity and decreases P2X7 receptor activity. AZ-1 activates endogenous LXR signaling but shows no direct LXRα or LXRβ agonist activity. |
|
T72590 |
α,β-Methylene-ATP
|
|
|
|
α,β-Methylene ATP, a phosphonic analog of ATP, functions as a ligand for P2X3 and P2X7 receptors. This compound acts primarily as a selective agonist for P2X1 and P2X3 receptors, exhibiting minimal to no activity on P2X2... |
|
T68696 |
AZ-2
|
|
|
|
AZ-2 is an inducer of ABCA1 and apoE. It enhances ABCA1 activity and decreases P2X7 receptor activity. AZ-2 activates endogenous LXR signaling but shows no direct LXRα or LXRβ agonist activity. |
|
T10466 |
BAY-1797
|
|
P2X Receptor
|
|
BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects. BAY-1797 displays no or very weak activity on the other P2X ion channels. |
|
T71651 |
GSK1370319A
|
|
|
|
GSK1370319A is a potent P2X7 antagonist (IC50 = 3.2 nM). GSK1370319A inhibits ATP-induced increase in IL-1β release and caspase 1 activation in lipopolysaccharide (LPS)-primed mixed glia by blocking assembly of the infla... |
|
T83802 |
TNP-ATP sodium
|
|
|
|
TNP-ATP, a derivative of ATP, acts as an antagonist to the purinergic P2Y1, P2X3, and P2X2/3 receptors, demonstrating selectivity by showing lower inhibitory concentrations (IC50 = 6, 0.9, 7 nM, respectively) compared to... |
|
T37313 |
ITH15004
|
|
|
|
ITH15004 is a non-nucleotide antagonist of the purinergic P2X7receptor (IC50= 9 μM in HEK293 cells expressing the human receptor).1It inhibits ATP-induced currents inX. laevisoocytes expressing the human P2X7receptor whe... |
